Rick Strassman

Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study

Retrieved on: 
Tuesday, March 16, 2021
Amines, Ayahuasca, Entheogens, N,N-Dimethyltryptamine, Psychoactive drugs, Rick Strassman

"I am pleased to collaborate with PharmaDrug on DMT in a novel research project that could provide new insights and a foundation on DMT's clinical utility for unmet medical needs."

Key Points: 
  • "I am pleased to collaborate with PharmaDrug on DMT in a novel research project that could provide new insights and a foundation on DMT's clinical utility for unmet medical needs."
  • Following the acquisition of Sairiyo Therapeutics and its biotech R&D core competencies, PharmaDrug has undertaken efforts to expand its research activities in the pharmaceutical psychedelics space.
  • Through engagement with respected academics and medical/clinical KOLs in the space, management will initiate pivotal preclinical and clinical development activities.
  • Taking advantage of existing expertise and relationships, PharmaDrug will seek to broaden its intellectual property portfolio by creating unique DMT formulations.

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Retrieved on: 
Monday, February 1, 2021
Psychoactive drugs, Hallucinations, Entheogens, Amines, Ayahuasca, Rick Strassman, N,N-Dimethyltryptamine, Psychedelic drug, Hallucinogen, Microdosing

Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration.

Key Points: 
  • Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration.
  • Named the Spirit Molecule by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, DMT has been shown to induce neuroplasticity in a number of key preclinical studies.
  • The Company has also retained Novotech to conduct a feasibility study for Algernon to conduct all or part of its DMT stroke clinical research program in Australia.
  • Algernon is also exploring conducting its DMT clinical research program in other countries as well.